Whittier Trust Co. of Nevada Inc. Has $75,000 Holdings in GSK plc (NYSE:GSK)

Whittier Trust Co. of Nevada Inc. raised its position in shares of GSK plc (NYSE:GSK) by 23.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,233 shares of the pharmaceutical company’s stock after purchasing an additional 417 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in GSK were worth $75,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Primecap Management Co. CA grew its position in shares of GSK by 70.1% during the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after buying an additional 10,407,905 shares during the period. FMR LLC grew its position in shares of GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the period. Mondrian Investment Partners LTD lifted its holdings in shares of GSK by 17.6% in the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock worth $205,920,000 after purchasing an additional 874,004 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

GSK has been the topic of a number of recent research reports. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley initiated coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of NYSE:GSK opened at $39.22 on Monday. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The stock’s fifty day simple moving average is $36.66 and its two-hundred day simple moving average is $36.87. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The stock has a market cap of $81.18 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.01%. GSK’s dividend payout ratio (DPR) is currently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.